These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20593220)

  • 1. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
    J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
    Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
    Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
    Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
    Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
    Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
    Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
    Nakamura M; Watanabe T; Yonekawa Y; Kleihues P; Ohgaki H
    Carcinogenesis; 2001 Oct; 22(10):1715-9. PubMed ID: 11577014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
    Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.
    Su Y; Yin L; Liu R; Sheng J; Yang M; Wang Y; Pan E; Guo W; Pu Y; Zhang J; Liang G
    Med Oncol; 2014 Feb; 31(2):784. PubMed ID: 24366688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
    Mulholland S; Pearson DM; Hamoudi RA; Malley DS; Smith CM; Weaver JM; Jones DT; Kocialkowski S; Bäcklund LM; Collins VP; Ichimura K
    Int J Cancer; 2012 Sep; 131(5):1104-13. PubMed ID: 22020830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma.
    Carlos-Escalante JA; Gómez-Flores-Ramos L; Bian X; Perdomo-Pantoja A; de Andrade KC; Mejía-Pérez SI; Cacho-Díaz B; González-Barrios R; Reynoso-Noverón N; Soto-Reyes E; Sánchez-Correa TE; Guerra-Calderas L; Yan C; Chen Q; Castro-Hernández C; Vidal-Millán S; Taja-Chayeb L; Gutiérrez O; Álvarez-Gómez RM; Gómez-Amador JL; Ostrosky-Wegman P; Mohar-Betancourt A; Herrera-Montalvo LA; Corona T; Meerzaman D; Wegman-Ostrosky T
    Cell Mol Neurobiol; 2021 Aug; 41(6):1285-1297. PubMed ID: 32535722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
    Gömöri E; Pál J; Kovács B; Dóczi T
    Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
    Carlos-Escalante JA; Mejía-Pérez SI; Soto-Reyes E; Guerra-Calderas L; Cacho-Díaz B; Torres-Arciga K; Montalvo-Casimiro M; González-Barrios R; Reynoso-Noverón N; Ruiz-de la Cruz M; Díaz-Velásquez CE; Vidal-Millán S; Álvarez-Gómez RM; Sánchez-Correa TE; Pech-Cervantes CH; Soria-Lucio JA; Pérez-Castillo A; Salazar AM; Arriaga-Canon C; Vaca-Paniagua F; González-Arenas A; Ostrosky-Wegman P; Mohar-Betancourt A; Herrera LA; Corona T; Wegman-Ostrosky T
    J Neurooncol; 2023 Jan; 161(1):165-174. PubMed ID: 36525166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.